Back to Stakeholders

Pioneer in modern American psychedelic research through Rick Strassman's DMT and psilocybin studies in the 1990s — among the first human psychedelic research since the 1970s. Today, UNM Health Sciences conducts active trials of psilocybin, MDMA, and ketamine for depression, PTSD, alcohol use disorder, and methamphetamine addiction.

Academic Research

0 papers

Published Papers

0

Trial Involvement

9

Distinct Focus Topics

0

Latest Publication

Unknown

Research journey

Built from the 8 trials University of New Mexico has sponsored, placed at the date each one started.

Clinical trial history8 sponsored trials · 3 lanes · 1 not yet startedtoday2012201620202024Psilocybin4 trialsKetamine3 trialsPhase 1/2 · PTSDMDMA1 trial · Phase 2Each dot is a trial, placed at its start date. Hover a dot for what it tests and how far it got.

Quick Facts

Type
Other
HQ
University of New Mexico, Albuquerque, United States
Website
Visit

Research Landscape

What the registered trials University of New Mexico sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of August 2026.

What's live right now, and what stopped?

Sourced

Registry status of all 9 University of New Mexico trials Blossom tracks. Orange marks trials recruiting or opening.

Recruiting or opening
333%
Completed
444%
Stopped early
222%

Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.

Sponsored Trials

8

Where this pipeline sits in the field

University of New Mexico runs late-stage trials that Blossom ranks by how soon a catalyst is expected, alongside every other Phase 2 and Phase 3 study in the field.

Open the forecast →

Collaborated Trials

1

Recent activity